Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) fell 14.6% on Monday . The company traded as low as C$1.24 and last traded at C$1.29. 551,069 shares were traded during trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.
Cardiol Therapeutics Trading Down 14.6%
The firm has a market cap of C$129.00 million, a price-to-earnings ratio of -3.15 and a beta of 1.31. The company has a fifty day moving average price of C$1.50 and a 200-day moving average price of C$1.65. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59.
Cardiol Therapeutics (TSE:CRDL – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. As a group, research analysts expect that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.
About Cardiol Therapeutics
Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
Featured Stories
- Five stocks we like better than Cardiol Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
- What is a SEC Filing?
- Congress Beat the Market Again—Here Are the 3 Stocks They Bought
- Health Care Stocks Explained: Why You Might Want to Invest
- Go on a Shopping Spree With 3 Top Retail ETFs
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
